The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial

Abstract

Objective This randomized, double-blind, controlled trial (RCT) aimed to evaluate the effect of Phyllanthus Emblica (Amla) as an add-on therapy on COVID-19_ related biomarkers and clinical outcomes in COVID-19 patients. Methods In this RCT, sixty-one patients were randomly assigned into two arms [the intervention (n=31) and control arms (n=30)]. The effect of Amla on diagnostic Reverse-transcription Polymerase Chain Reaction (RT-PCR) test results between the first and the last days of the study, the length of stay (LOS) in hospital, the percentage of lung involvement on CT scans, changes in the clinical symptoms, and the laboratory markers were assessed. Results The two study groups had similar baseline demographics and characteristics in terms of medical history. The mean of LOS in the intervention arm (4.44 days) was significantly shorter than in the control arm (7.18 days, P<0.001); RT-PCR results were not significantly different between the two arms (P=0.07). All clinical variables decreased over time in the two groups (P<0.001). However, the difference between the two groups in terms of fever (P=0.004), severity of cough (P=0.001), shortness of breath (P=0.004), and myalgia (P=0.005) were significant, but this intergroup comparison was not significant with regard to respiratory rate (P=0.29), severity of chills (P=0.06), sore throat (P=0.22), and weakness (P=0.12). Out of the eight evaluated para-clinical variables, three variables showed significant improvement in the intervention arm, including the mean increase in oxygen saturation (SpO2) level (P<0.001), the reduction in the mean percentage of lung involvement on CT (P<0.001), and the improvement in C-reactive protein test results (P<0.001). Conclusion Organic herbal Amla tea cannot significantly affect the RT-PCR results and or degree of lung involvement. Nevertheless, it showed an ameliorative effect on the severity of clinical signs and CRP levels. Also, Amla tea may shorten the recovery times of symptoms and LOS in COVID-19 patients.

Traditional Vietnamese medicine Kovir capsule for non‐severe COVID‐19 patients: A phase III double‐blind randomized controlled trial

“…Kovir shares the main feature with other herbal and traditional medicines, including healing and restoring the balance of the body (Ang et al, 2022; Chen et al, 2022; Devpura et al, 2021; Jiang et al, 2021; Karimi et al, 2021; Li et al, 2022; Natarajan et al, 2021; Srivastava et al, 2021; Tseng et al, 2022; Valizadeh et al, 2020; Varnasseri et al, 2022; Xia et al, 2021; Xiao et al, 2020; Xu et al, 2021; X. Y. Zhang et al, 2021; Zhou et al, 2021). The mechanism of this feature may be that Kovir contains several anti‐inflammatory components such as Radix Peucedani , Radix Bupleuri chinensis , Radix Codonopsis pilosulae , and Radix Angelicae pubescentis .…”

Phenolic compounds versus SARS-CoV-2: An update on the main findings against COVID-19

“… Hospitalization was 4,5 days shorter. Varnasseri et al (2022) Controlled, randomized, double-blind. 30 patients.…”

Effectiveness of traditional Vietnamese medicine Kovir capsule in adults with mild COVID‐19: A propensity score‐matched study

“…Many herbal and traditional medicines have also been investigated for the treatment of COVID‐19 in some countries with well‐known traditional medicine such as China, India, and Iran (Chen et al, 2022 ; Devpura et al, 2021 ; Jiang et al, 2021 ; Karimi et al, 2021 ; Natarajan et al, 2021 ; Srivastava et al, 2021 ; Valizadeh et al, 2020 ; Varnasseri et al, 2022 ; Xia et al, 2021 ; Xiao et al, 2020 ; Xu et al, 2021 ; Zhang, Lv, et al, 2021 ; Zhou et al, 2021 ). A highlighted feature of herbal and traditional medicines is symptom relief that can reduce time to symptom resolution and prevent the progression to severe disease.…”